Table 5.

Differential metabolites of GCF between patients with ESRD and healthy controls

Metabolic pathway	Metabolites	Mean (ESRD)	Mean (HC)	Fold change	Log_fold change	AUC value
Nicotinate and nicotinamide metabolism	Niacinamide	0.0361	0.1008	0.359	− 1.479	0.703
	N1-Methyl-2-pyridone-5-carboxamide	0.3889	0.0505	7.701	2.945	0.952
Phenylalanine metabolism	m-Coumaric acid	1.5604	2.4824	0.629	− 0.670	0.748
	Hydrocinnamic acid	10.0707	32.8998	0.306	− 1.708	0.823
Taurine and hypotaurine metabolism	Taurine	5.7182	9.2706	0.617	− 0.697	0.778
	3-Sulfinoalanine	1.1994	2.0963	0.572	− 0.806	0.747
Purine metabolism	Inosine	0.1574	0.3363	0.468	− 1.095	0.843
	Xanthine	0.9294	1.2673	0.733	− 0.447	0.687
	Hypoxanthine	26.5315	42.3163	0.627	− 0.674	0.768
Galactose metabolism	alpha-d-Glucose	0.0889	0.0099	8.961	3.164	0.714
	Raffinose	0.0408	0.0013	32.389	5.017	0.740
Starch and sucrose metabolism	d-Maltose	0.5640	0.0761	7.413	2.890	0.744
Pyrimidine metabolism	Uridine	2.9903	5.2445	0.570	− 0.810	0.793
	dUMP	0.0358	0.0041	8.692	3.120	0.709

GCF, gingival crevicular fluid; ESRD, end-stage renal disease; HC, healthy controls; AUC, area under curve